Certain identified information has been omitted from this exhibit because it is not material and of the type that the registrant treats as private or confidential. [***] indicates that information has been omitted. SAMSUNG BIOLOGICS CO., LTD. PRODUCT...Product Specific Agreement • December 23rd, 2021 • Environmental Impact Acquisition Corp • Biological products, (no disgnostic substances)
This Product Specific Agreement (this “PSA”) is made effective as of the date of last signature below (the “PSA Effective Date”) by and between GreenLight Biosciences, Inc., a Delaware corporation having its principal place of business at 200 Boston Avenue, Suite 1000, Medford, MA 02155 (“Client”) and Samsung Co., Ltd., a Korean corporation having its principal place of business at 300, Songdo bio-daero, Yeonsu-gu, Incheon, 21987, Republic of Korea (“SBL”). Client and SBL are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
SAMSUNG BIOLOGICS CO., LTD. PRODUCT SPECIFIC AGREEMENT – COMMERCIAL PRODUCT DRUG SUBSTANCEProduct Specific Agreement • July 25th, 2024 • Kiniksa Pharmaceuticals International, PLC • Pharmaceutical preparations
This Product Specific Agreement (this “PSA”) is made effective as of June 21, 2024 (the “PSA Effective Date”) by and between Kiniksa Pharmaceuticals (UK), Ltd., a private company organized under the laws of England and Wales with a Swiss branch office located at Grafenaustrasse 5, 6300 Zug, Switzerland (“Client”) and Samsung BioLogics Co., Ltd., a Korean corporation having its principal place of business at 300, Songdo bio-daero, Yeonsu-gu, Incheon, 21987, Republic of Korea (“SBL”). Client and SBL are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
Certain identified information has been excluded because it is both not material and would likely cause competitive harm if publicly disclosed. SAMSUNG BIOLOGICS CO., LTD. PRODUCT SPECIFIC AGREEMENT COMMERCIAL DRUG SUBSTANCEProduct Specific Agreement • August 14th, 2019 • CytoDyn Inc. • Pharmaceutical preparations
ContractProduct Specific Agreement • March 1st, 2021 • Fibrogen Inc • Pharmaceutical preparations
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.
SAMSUNG BIOLOGICS CO., LTD. PRODUCT SPECIFIC AGREEMENT - COMMERCIAL PRODUCT DRUG SUBSTANCEProduct Specific Agreement • November 7th, 2018 • Immunomedics Inc • In vitro & in vivo diagnostic substances
This Product Specific Agreement (this “PSA”) is made effective as of the date of last signature below (the “PSA Effective Date”) by and between Immunomedics, Inc., a Delaware corporation having its principal place of business at 300 The American Rd, Morris Plains, NJ 07950 (“Client”) and Samsung BioLogics Co., Ltd., a company with offices at 300, Songdo bio-daero, Yeonsu-gu, Incheon, 21987, Republic of Korea (“SBL”). Client and SBL are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
